Currently, the first-line treatment for ER+/HER2− luminal and HER2+ breast cancer patients respectively combines antiestrogens with cyclin-dependent 4/6 kinase (CDK 4/6) inhibitors and monoclonal antibodies against specific HER2 epitopes, along with chemotherapy. The gene discussed is ESR1; the disease is breast carcinoma.